A new report analyzing 2019 securities litigation suggests the volume of class actions and the size of their settlements will likely continue at high levels in upcoming years, especially in the already hard-hit pharmaceutical sector.

That’s the main takeaway for general counsel from the “Securities Class Action Settlements—2019 Review and Analysis,” according to Laura Simmons, the report’s co-author and a senior research adviser at Cornerstone Research.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]